Protein synthesis is required for many critical cellular processes, and cells regulate mRNA translation rates according to their needs. Interestingly, dysregulated translation has now been linked to multiple human cancers (1, 2) . Increased translation rates lead to an overproduction of proteins involved in proliferation, survival, metastasis, and other malignant characteristics (3) (4) (5) . Protein synthesis regulation is complex, and its alteration in tumor cells occurs at numerous points. Many tumor-promoting mechanisms ultimately cause the activation of a critical regulator of capdependent translation, the eukaryotic translation initiation factor 4F (eIF4F) complex. Numerous human tumors exhibit inappropriate eIF4F activation, including lymphomas and breast, prostate, colorectal, head and neck, cervical, bladder, and lung cancers (3). Therefore, therapeutically targeting eIF4F activity is exceedingly attractive, as it would potentially be applicable to a broad range of human cancers. In this issue of the JCI, Graff and colleagues (6) report such a strategy, attacking one of the important components of eIF4F, eIF4E, with striking efficacy in tumor models. If this treatment is successful in the clinic, it holds great promise for use against many human tumors and may be especially effective if used in combination with more traditional chemotherapeutic treatments.
Cap-dependent protein synthesis and its regulation
To provide better insight into the underlying mechanism for this therapy and why it might ultimately be so effective against cancer, we will briefly describe cap-dependent mRNA translation and its regulation. Translation initiation is primarily controlled by the assembly of two multiprotein complexes and their association with mRNA: the ternary and eIF4F complexes (7). The ternary complex consists of eIF2a, guanosine triphosphate (GTP), and a methionine-charged transfer RNA. It associates with the 40S ribosome and then the 7-methyl-GTP-capped mRNA, which is bound to eIF4F. eIF4F is comprised of the scaffold eIF4G, the ATP-dependent RNA-helicase eIF4A, and the cap binding protein eIF4E. The convergence of these complexes on mRNA allows ribosome scanning and translation initiation. Since eIF4E is the least abundant component, its availability limits translation initiation rates, and therefore translation itself. Free eIF4E levels are determined primarily by their degree of association with a class of regulatory proteins termed eIF4E binding proteins (4E-BPs). 4E-BPs bind to eIF4E at the eIF4G binding site and therefore block eIF4F assembly by sequestering its rate-limiting member. The 4E-BPs (there are three family members) are regulated in turn by phosphorylation at several sites, with increased phosphorylation leading to decreased eIF4E binding capacity. 4E-BP phosphorylation is carried out primarily by the mammalian target of rapamycin complex 1 (mTORC1) (8) . mTORC1 gathers information about the cellular environment, including nutrient, growth factor, and oxygen availability and activates downstream effectors accordingly (2, 9). mTORC1 phosphorylates two key substrates, p70 S6K , whose activity mediates the binding of several key initiation factors (10), and 4E-BPs. This way, mTORC1 integrates the richness of the environment with biosynthetic pathways downstream, dictating whether cells will grow and proliferate. Importantly, key points in the pathway that activate mTORC1 are frequently mutated in human cancers. For example, PI3K activity is often high in tumors due to the loss of the PTEN tumor suppressor, which allows a constitutive activation of the AKT kinase, inappropriate mTORC1 signaling, and constitutive phosphorylation and inactivation of 4E-BPs (2). Due to the important role of mTORC1 in cell growth and proliferation, multiple mTORC1 inhibitors are progressing through clinical trials. eIF4E availability dictates not only the rate of protein synthesis but, perhaps more importantly, its quality. It has been proposed that the mRNA 5′ untranslated region (5′UTR) structure in part dictates translation efficiency (reviewed in ref.
3). mRNAs with highly complex 5′UTR structures ("weak" mRNAs) are more difficult to translate than those with relatively uncomplicated structures ("strong" mRNAs). This model postulates that strong mRNAs are translated at a relatively constant rate with little impact from active initiation factor availability. Conversely, because weak mRNAs must compete for eIF4E binding and retention, they are translated much more efficiently when eIF4E is present in excess. Importantly, weak mRNAs tend to be those with roles in proliferation (cyclin D1, c-Myc, and ornithine decarboxylase), survival (Bcl-x L , etc.), angiogenesis (VEGF,
Figure 1
Mechanism of action of eIF4E ASOs. (A) In normal tissues, eIF4E is typically sequestered by hypophosphorylated 4E-BPs, resulting in restricted translation rates. Homeostasis is maintained by limiting translation to essential genes, such as housekeeping genes. (B) In some tumors, oncogenic signaling results in primarily hyperphosphorylated 4E-BPs. Additionally, many tumors express high levels of eIF4E. Excess free eIF4E leads to increased translation rates, especially of genes involved in proliferation, survival, and metastasis. These increased translation rates help to drive tumor progression. (C) In tumors treated with eIF4E ASOs, eIF4E levels are significantly reduced. Despite 4E-BP hyperphosphorylation, reduced eIF4E levels inhibit translation rates, causing growth arrest or even apoptosis in tumors. It is likely that this strategy would have broad-reaching applications for tumors with eIF4E overexpression, oncogenic signaling (leading to 4E-BP hyperphosphorylation), or both. Since tumors frequently rely on increased translation for high proliferation rates and other malignant properties, reducing eIF4E levels should have a greater impact on them than it would on normal cells.
basic FGF, and HIF-1a), and other malignancy-promoting functions (MMP9, etc.) (3). Therefore, targeting eIF4F would allow the clinician to hit a variety of gene targets with one therapy, since increased translation rates alter the expression of a variety of genes. In addition, targeting an essential component of translation initiation at a point far downstream should allow little chance of escape via activating upstream components of the pathway. However, as attractive as this strategy is, little success has followed attempts to therapeutically attack the eIF4F complex. First, because eIF4F function is dictated by protein-protein interactions and mRNA binding, complex disruption has proven to be extremely difficult. Additionally, the potential offtarget effects of eliminating an essential component of the translation machinery are troubling. Graff et al. (6) report the use of second-generation antisense oligonucleotides (ASOs) to effectively downregulate eIF4E in tumors, greatly attenuating tumor growth in breast and prostate cancer models. In addition, and perhaps surprisingly, no toxicity was detected using this strategy. These results raise the possibility of effectively attacking protein translation downstream of mTORC1 in the clinic.
Effects of eIF4E downregulation in tumors and other tissues
The use of eIF4E ASOs was previously shown to have the predicted effect of reversing transformation (11, 12) . However, this strategy was not generally effective due to the difficulties of using ASOs therapeutically. Graff and colleagues (6) utilized second-generation ASOs, which are modified to enhance their tissue half-life. They show that treatment of cells in culture with these oligonucleotides caused a significant decrease in eIF4E expression, leading to decreased expression of cyclin D1 and VEGF (both eIF4E translational targets), without a drop in global protein synthesis. They also demonstrated cytotoxicity in vitro, an important observation in light of the potential antitumor effects of eIF4E ASOs. The most interesting data, however, were generated in vivo: mice with subcutaneous xenograft tumors were treated with eIF4E ASOs, causing a profound reduction in tumor growth. eIF4E ASO administration resulted in an approximately 50% decrease in eIF4E levels within tumors. This level of downregulation almost completely prevented tumor growth, whereas tumors in control-treated mice continued to grow.
In addition, treatment with eIF4E ASOs downregulated tumor VEGF levels and decreased the overall vessel number within the tumors. The authors then addressed an important question: the potential systemic toxicity that eIF4E downregulation might be predicted to cause. Strikingly, despite a highly significant downregulation (approximately 70%) of eIF4E in the liver, there was no overall toxicity and no negative effects on liver transaminase levels. It is perhaps somewhat surprising that such a substantial decrease in eIF4E abundance does not negatively impact liver function. Since most housekeeping genes are strong mRNAs, however, low eIF4E levels might be sufficient to translate them ( Figure 1 ). This is a critically important point for the future use and efficacy of eIF4E ASOs, and more testing is certainly in progress to assess its overall effects.
The promises and questions of eIF4E therapy in human tumors
The results presented by Graff et al. (6) are very exciting for human tumor treatment. Some questions remain, however, and must be addressed as this strategy moves forward. It will be necessary to further examine mechanisms of eIF4E ASO function. Clearly, treating cells in vitro with eIF4E ASO induced apoptosis. It is likely that treatment in vivo also causes apoptosis, though this will have to be more carefully examined. Tumors treated with eIF4E ASO did not grow, but neither did they regress, essentially remaining the same size. It will be necessary to determine whether eIF4E ASOs act cytotoxically or cytostatically. It is possible that eIF4E ASOs do not reach a high enough concentration in the xenografts to cause the level of cell death observed in vitro. Alternatively, lowering eIF4E levels in these tumors might simply arrest proliferation. This will be an important point, as the ultimate goal of tumor therapy is the death of tumor cells. If eIF4E ASOs act solely cytostatically, their use as single-agent therapeutics might be limited. However, an approach that could be highly productive might combine eIF4E ASOs with traditional cytotoxic chemotherapeutics. This drug combination would be especially effective if eIF4E ASO treatment lowers the tumor cell apoptotic threshold. In conjunction, these agents together would likely induce massive tumor cell apoptosis.
The ability to treat tumors exhibiting high eIF4E levels is very exciting for several reasons. First, as mentioned above, many tumors have been described in which eIF4E is overexpressed (Figure 1 ), potentially promising broad application. Furthermore, many tumors, such as PTEN, have mutations in upstream components of the pathway that ultimately regulate eIF4E, and such tumors should be susceptible to therapy aimed downstream of these components. Second, small increases in eIF4E expression have profound effects on tumor promotion (13) , increasing the likelihood of eIF4E ASO efficacy. Third, it is known that eIF4E overexpression results in resistance to rapamycin (14, 15) and rapamycin/chemotherapy combination (16) , so this treatment would offer an alternative for patients with rapamycinresistant tumors. This excitement is not without caveats however. It is also possible that combination therapy (or eIF4E ASO treatment alone) could lower the apoptotic threshold in certain normal tissues. In this scenario, lowering eIF4E levels would have a profoundly deleterious impact on tissues such as the liver, among others, complicating the dosage and benefit. In addition, immune system effects will have to be assessed: multiple immune responses require massive cell proliferation and production of soluble mediators that naturally require the synthesis of new proteins. Thus severely decreasing systemic eIF4E levels might also be detrimental to immune function. Indeed rapamycin, which should inhibit eIF4F activity, was originally used as an immunosuppressive agent, and as such, eIF4E downregulation may have an impact on the efficacy of the immune response. Graff and colleagues assessed splenic mass, which was not changed relative to controls, although these parameters will need to be examined in actively proliferating cells such as those responding to an infection.
Summary and future directions
Despite these potential hurdles, the data presented by Graff et al. (6) offer exciting and broad-reaching potential for the treatment of many forms of human cancer. Future experiments must address the mechanism(s) by which eIF4E ASOs function. Additionally, potential off-target effects must be assessed, especially in situations in which tissues are stressed or must proliferate. However, this approach holds great promise: attacking the eIF4F complex has been recognized as a potentially excellent therapeutic approach for some time. The difficulty in disrupting this complex therapeutically has made it unproductive in the clinic so far. With the development of second-generation ASOs for eIF4E, Graff and colleagues may enable us to finally target this important complex effectively, providing a potentially wide-ranging antitumor modality.
